Immunology and Microbiology
Myeloid
100%
Graft-Versus-Host Disease
80%
Cell Transplantation
71%
Hematopoietic Cell
71%
Cyclophosphamide
55%
Colitis
46%
Allotransplantation
41%
Chronic Graft Versus Host Disease
40%
Acute Graft Versus Host Disease
37%
Ciclosporin
34%
Recurrence Free Survival
31%
Cytotoxic T-Cell
29%
Conditioning
26%
Overall Survival
26%
Immunosuppressive Therapy
25%
Epitope
23%
Mouth Mucosa
23%
Stem Cell Transplantation
23%
Immunosuppression
23%
Stem Cell
23%
Hematopoiesis
23%
Aplastic Anemia
23%
Ulcerative Colitis
23%
Heavy Chain
23%
Genotype Phenotype Correlation
23%
Inflammatory Bowel Disease
18%
Allogeneic Stem Cell Transplantation
15%
Transplant Procedure
14%
CD68
14%
T-Helper Cell
11%
Anti-Thymocyte Globulin
11%
Penetrance
11%
Carboxy Terminal Sequence
11%
Autosomal Dominant Inheritance
11%
Crohn's Disease
10%
Allogeneic Hematopoietic Stem Cell Transplantation
9%
Mycophenolic Acid
9%
Cell Infiltration
9%
Colon
9%
Drug Megadose
9%
Macrophage
9%
Survival Rate
7%
Gene Frequency
7%
Mucosa
5%
Somatic Mutation
5%
Event Free Survival
5%
Immune Cell Infiltration
5%
Medicine and Dentistry
Graft Versus Host Reaction
76%
Acute Myeloid Leukemia
73%
Cell Transplantation
53%
Hematopoietic Stem Cell
53%
Cyclophosphamide
51%
Decitabine
46%
Immunosuppressive Treatment
46%
Hazard Ratio
34%
Allotransplantation
34%
Cyclosporine
32%
Acute Graft Versus Host Disease
29%
Recurrence Free Survival
27%
Conditioning
27%
Overall Survival
25%
Myeloid Malignancy
23%
Aplastic Anemia
23%
Minimal Residual Disease
23%
Whole Body Radiation
23%
Fludarabine
23%
Eltrombopag
23%
Retrospective Study
23%
Stem Cell Therapy
23%
Acute Leukemia
23%
Disease
23%
Hypomethylating Agent
23%
Acute Myelogenous Leukemia
23%
MYH9
23%
Colitis
23%
Genotype Phenotype Correlation
23%
Allogeneic Stem Cell Transplantation
18%
Inflammatory Bowel Disease
18%
Chronic Graft Versus Host Disease
17%
Nonmyeloablative Conditioning
15%
Transplantation
13%
Recurrence Risk
12%
Cumulative Incidence
11%
Mycophenolic Acid
9%
Allogeneic Hematopoietic Stem Cell Transplantation
9%
Thymocyte Antibody
9%
Survival Rate
9%
T-Helper Cell
8%
Cytotoxic T-Cell
8%
Cohort Analysis
7%
Macrophage
6%
Chlordane
6%
Multivariate Analysis
5%
Leukemia
5%
Drug Megadose
5%
End Stage Renal Disease
5%
Nephropathy
5%
Keyphrases
Pretransplant
23%
Conventional Chemotherapy
23%
Checkpoint Inhibitor Colitis
23%
Acute Myeloid Leukemia
23%
HLA Epitopes
23%
Minimal Residual Disease
23%
Hematopoietic Cell Transplantation
23%
Decitabine
23%
Older Patients
23%
Oral mucosa
23%
Ruxolitinib
23%
Immunosuppression
23%
Eltrombopag
23%
Steroid-refractory
23%
Graft-versus-host Disease (GvHD)
23%
Mobilization Failure
23%
Oral Participation
23%
Severe Aplastic Anemia
23%
MYH9-related Disease
23%
Clinical Evolution
23%
Older AML
23%
Immunosuppressive Therapy
20%
Complete Response
16%
Poor Mobilizers
15%
Poor Mobilization
11%
Intensive Chemotherapy
10%
Antithymocyte Globulin
9%
Previously Untreated Patients
9%
Cyclosporine
9%
Hematological Response
9%
HLA Matching
8%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
7%
Partial Response
6%
Overall Survival
6%
ELN 2017
5%
Predictive Value
5%
Subdistribution Hazard Ratio
5%
